State Street® SPDR® S&P® Pharmaceuticals ETF XPH

Medalist Rating as of | See State Street Investment Hub

Morningstar’s Analysis XPH

Will XPH outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

State Street® SPDR® S&P® PhrmctlsETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings XPH

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 26.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Xeris Biopharma Holdings Inc

2.68 12M
Healthcare

Veradermics Inc

2.64 12M
Healthcare

Pacira BioSciences Inc

2.58 12M
Healthcare

Eli Lilly and Co

2.54 12M
Healthcare

Amneal Pharmaceuticals Inc Ordinary Shares - Class A

2.41 11M
Healthcare

Zoetis Inc Class A

2.30 11M
Healthcare

Viatris Inc

2.30 11M
Healthcare

Pfizer Inc

2.24 10M
Healthcare

Maze Therapeutics Inc

2.23 10M
Healthcare

Perrigo Co PLC

2.23 10M
Healthcare

Sponsor Center